Therma Bright amends agreement to secure stakes in InStatin and InVixa

Therma Bright Inc (TSX-V:THRM, OTC:TBRIF) has modified its acquisition agreement with August Therapeutics and Ketiko Bio Corp, aiming to acquire a 25% stake in InStatin, Inc. and InVixa, Inc. The amended deal involves issuing a total of 55 million shares to the vendors and obtaining options for additional shares in InStatin, contingent on cash payments.